Fewer than 15% of GCC HAE patients are on any prophylaxis versus 35 to 40% in the US, making this category creation, not share capture.

An estimated 400-600 GCC HAE patients exist across the six GCC countries, with prophylaxis penetration below 15% versus roughly 35-40% in the US. Takeda's Takhzyro (lanadelumab) is SFDA-registered but accesses the market almost exclusively through voluntary health insurance at private hospitals and limited KFSH&RC exceptional access; NPHC does not list HAE prophylaxis as a routine benefit. The never-prophylaxed population, roughly 350-500 patients managing on acute C1-INH agents alone, is the primary commercial target, not a switch cohort from an entrenched competitor.

Diagnosis itself is a gating factor: SERPING1 genetic testing and C1-INH functional assays are concentrated at KFSH&RC and a small number of GCC labs, and an estimated 30-50% of true HAE burden remains undiagnosed. Abdominal attacks, which account for 50-70% of all HAE attacks, are frequently misdiagnosed in GCC as gastroenteritis, appendicitis, or gynaecological conditions, and an estimated 30-40% of GCC HAE patients undergo unnecessary abdominal surgery before correct diagnosis. Laryngeal attacks carry acute mortality risk, compounded by geographic dispersion: rural patients in the Eastern Province and Najd regions face two-to-four-hour transport times to a C1-INH-stocked hospital.

This is category creation in a never-prophylaxed market, not a switch fight.

Five questions this report answers:

Q1 - What must a new HAE prophylaxis agent prove to create a category under 15% prophylaxed?

Q2 - How large is the never-prophylaxed and undiagnosed GCC HAE population, and how is it found?

Q3 - What VHI and NPHC groundwork needs to start before SFDA approval?

Q4 - What determines whether a pre-launch HAE prophylaxis agent succeeds commercially in the GCC?

Q5 - What deliverables and sourcing standard does every AXLRx GCC HAE assessment include?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#HereditaryAngioedema #GCC #SFDA #RareDisease #LaunchReadiness #Immunology

Live report page:  https://axlrx.ai/hereditary-angioedema/gcc/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/